

STATE-OF-THE-ART REVIEW

Paraoxonase-1 and Early-Life Environmental Exposures



Judit Marsillach, PhD, Lucio G. Costa, PhD, Clement E. Furlong, PhD
Seattle, WA; and Parma, Italy

Abstract

Acute and chronic exposures to widely used organophosphorus (OP) insecticides are common. Children's detoxification mechanisms are not well developed until several years after birth. The increased cases of neurodevelopmental disorders in children, together with their increased susceptibility to OP neurotoxicity cannot be explained by genetic factors alone but could be related to gene-environment interactions. Paraoxonase-1 (PON1) is an enzyme that can detoxify OPs but its catalytic efficiency for hydrolysis to certain OPs is modulated by the Q192R polymorphism. Studies with animals have provided important information on the role of PON1 in protecting against gestational and postnatal toxicity to OPs. The *PON1*_{Q192} allele is less efficient in hydrolyzing certain OPs than the *PON1*_{R192} allele. Maternal PON1 status (PON1 activity levels, the most important measurement, and functional Q192R phenotype) modulates the detrimental effects of exposure to the OP chlorpyrifos oxon on fetal brain gene expression and biomarkers of exposure. Epidemiologic studies suggest that children from mothers with lower PON1 status who were in contact with OPs during pregnancy tend to show smaller head circumference at birth and adverse effects in cognitive function during childhood. Infants and children are vulnerable to OP toxicity. The detrimental consequences of OPs on neurodevelopment can lead to future generations with permanent cognitive problems and susceptibility to develop neurodegenerative diseases. Improved methods using mass spectrometry to monitor OP-adducted biomarker proteins are needed and will be extremely helpful in early life biomonitoring, while measurement of PON1 status as a biomarker of susceptibility will help identify mothers and children highly sensitive to OPs. The use of adductomics instead of enzymatic activity assays for biomonitoring OP exposures have proved to provide several advantages, including the use of dried blood spots, which would facilitate monitoring newborn babies and children.

KEY WORDS early-life exposures, environmental health, organophosphates, neurodevelopment, paraoxonase-1

© 2016 The Authors. Published by Elsevier Inc. on behalf of Icahn School of Medicine at Mount Sinai. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

INTRODUCTION

Although some organophosphorus (OP) insecticides are being phased out in the United States, they are still widely used in developing countries. It is estimated

that each year there are 3 million insecticide poisonings worldwide with 220,000 deaths.¹ About 33 million pounds of OP insecticides were used in 2007 in the United States,² mostly for the control of pests in agricultural settings. According to the American

Association of Poison Control Centers' National Poison Data System (NPDS), about 32% of the OP insecticide exposures reported in 2013 involved children.³ Routes of OP exposure include ingestion, inhalation, and dermal contact in occupational, residential, and nonresidential settings. The frequency of neurodevelopmental disorders in children seems to be increasing worldwide. Developmental disabilities include specific learning and intellectual disabilities, autism, and attention deficit-hyperactivity disorders.⁴ Genetic factors only explain up to 40% of the neurodevelopmental disabilities reported. Growing evidence suggests that environmental exposures in combination with individual genetic susceptibility could trigger these disorders. This review focuses on gene-environment interactions important for modulating exposures to specific OP insecticides in early life.

More than 6 decades ago, the plasma enzyme paraoxonase-1 (PON1) was shown to hydrolyze toxic metabolites of OP insecticides.^{5,6} Early observations noted that species with high plasma paraoxonase levels were more resistant to parathion exposures than species with low plasma paraoxonase levels.^{7,8} Thus, for more than 4 decades it was thought that PON1 could protect against exposure to parathion as well as other OP compounds.⁹ As noted here, experiments in mice with genetically modified *PON1* genes, showed that human PON1 modulates sensitivity primarily to chlorpyrifos (CPS) and diazinon (DZS), especially for direct exposure to their oxon forms present in most, if not all exposures.⁹⁻¹² It is worth noting that all of the safety studies for chlorpyrifos oxon (CPO) have been carried out with highly pure, less-toxic parent compound CPS.¹³ More valid safety studies should be carried out with exposures containing a percentage of CPO representative to that found in actual exposures.

Several important questions arise from these early observations.

1. Does human plasma PON1 protect against exposure to specific OP compounds?
2. If so, is there genetic and or developmental variability in the plasma levels of PON1 among individuals?
3. Is there developmental regulation of plasma PON1 levels in early life?
4. Is a mother's plasma PON1 protective against OP exposures for her fetus(s)?

In this review, we examine these 4 important questions.

The question of the ability of PON1 to protect against OP exposure was directly tested in 1956 in

experiments where partially purified rabbit PON1 was injected into rats increasing their A-esterase activity 4 to 5 times and decreasing the toxicity of injected paraoxon (PO).¹⁴ This observation was repeated and extended to the effects of PON1 on CPO toxicity in another study.¹⁵ Many further experiments were carried out in mice showing PON1 protection against CPO and its parent compound CPS. A study in mice injected with rabbit PON1 clearly demonstrated that high levels of PON1 protected against exposure to both CPO and CPS.¹⁶ The effects of low levels of plasma PON1 were examined in *PON1* knockout (*PON1*^{-/-}) mice, which were shown to be dramatically sensitive to CPO¹⁷ and diazoxon (DZO), with less dramatically increased sensitivity to their respective parent compounds CPS and DZS.⁹ Surprisingly, the *PON1*^{-/-} mice showed no increased sensitivity to PO,⁹ indicating that mouse PON1 does not have a role in detoxifying PO *in vivo*, despite PON1 having been named for its ability to hydrolyze PO *in vitro*. Resistance to CPO and DZO could be restored by the injection of purified human PON1₁₉₂ alloforms, with both alloforms (Q and R) providing equal protection against DZO and the PON1_{R192} alloform providing better protection against CPO, in agreement with the respective catalytic efficiencies for hydrolysis of these 2 OPs by each PON1₁₉₂ alloform. Also in agreement with the lack of increased sensitivity of the *PON1*^{-/-} mice to PO, injection of neither human PON1₁₉₂ alloform protected against PO exposure in contrast to rabbit PON1. Injection into *PON1*^{-/-} mice of engineered recombinant human PON1 (rHuPON1) with lysine replacing arginine or glutamine at position 192 provided further evidence for the importance of high catalytic efficiency in PON1 protecting against OP exposure.¹⁸ The rHuPON1_{K192}, when injected into *PON1*^{-/-} mice, protected against 2 or 3 LD₅₀ levels of exposures of the *PON1*^{-/-} mice to DZO. The rHuPON1_{K192} has higher catalytic efficiency for the hydrolysis of DZO, CPO, and PO than the native PON1₁₉₂ Q or R alloforms and was designed based on the high catalytic efficiency of rabbit PON1 for hydrolysis of CPO.


These experiments clearly demonstrate the importance of PON1 in protecting against CPS and DZS exposures, especially to the oxon forms present in these exposures.⁹ They also point out the potential for treating acute, life-threatening OP exposures with injections of rHuPON1 or engineered rHuPON1, which will be necessary for treating exposures to parathion/PO.^{9,16,18}

Because PON1 plays an important role in resistance to exposure by at least 2 commonly used OP insecticides, the role of genetic and developmental variability become important questions related to early-life exposures. PON1 is a polymorphic enzyme. Studies in the 1960s and 1970s used PO as the substrate to measure PON1 activity in human populations. Most of them reported a high variability of PON1 activity between individuals, showing either a bimodal or trimodal distribution of serum PON1 activity levels¹⁹ leading to the suggestion that the paraoxonase activity of PON1 exhibited a genetic polymorphism.²⁰ Several assays were developed to examine this polymorphic distribution of PON1 activity, all used PO as a substrate under varying conditions of pH, salt concentration, calcium, buffer composition, and EDTA. Interestingly, this polymorphic distribution was not observed when using phenyl acetate as a substrate. Taking advantage of these substrate differences, an improved PON1 phenotype resolution was achieved by measuring PON1 activity with the two different substrates PO and phenyl acetate. This 2-substrate assay/analysis, pioneered in La Du's laboratory²¹ clearly resolved individuals with low PON1 activities by plotting rates of PO (with high salt in the assay) versus phenyl acetate, however, the intermediate and high metabolizers were not resolved by this 2-dimensional analysis. Cloning and sequencing of the human *PON1* gene revealed 2 major coding polymorphisms, L55M and Q192R.²² The basis of the high versus low rates of PO hydrolysis was subsequently shown to be determined by the Q192R polymorphism with the PON1_{R192} alloform hydrolyzing PO much more efficiently than the PON1_{Q192} alloform.^{23,24} Further improvement of this 2-substrate analysis, referred to as PON1 status,²⁵ involved plotting rates of DZO hydrolysis versus PO hydrolysis.^{26,27} This assay clearly resolved all three PON1₁₉₂ phenotypes (Q/Q, Q/R, and R/R). Results obtained from PON1 status analyses show inter- and intra-assay reproducibility, although samples should be analyzed within 2 years from collection.²⁸ A version of the PON1 status analysis that makes use of non-highly toxic substrates has recently been developed to reduce exposure of laboratory personnel to the highly toxic oxons PO and DZO.²⁹

A typical PON1 status plot (for 704 individuals) is shown in Figure 1.³⁰ This plot also shows the importance of the functional analysis of the 2-dimensional PON1 status plot. The activity

level for each individual is revealed by the plot, which also identified 4 individuals where the functional analysis was discrepant from the DNA single nucleotide polymorphism (SNP) analysis. Sequencing the *PON1* gene from these individuals revealed the defect in 1 allele in each, where the individuals genotyping as *PON1*₁₉₂ heterozygotes functionally showed only 1 active PON1 alloform. It is important to note that for epidemiologic studies, an SNP analysis provides only information about the PON1 SNPs present in the individual's genome and no information about the PON1 activity levels, the most important factor in determining risk for exposure or disease. One could characterize all ≈ 200 SNPs (Fig. 2) and not be able to predict PON1 activity level. We emphasize this point because many dozens of epidemiologic studies have been carried out using only an analysis of SNPs, ignoring the most important factor affecting risk, which is PON1 activity level.³¹

The question of developmental regulation of PON1 activity levels has been examined in at least 2 recent studies. One reported that PON1 levels of newborns are approximately one-third to one-fourth the levels of adults. It takes between 6 and 24 months for the PON1 levels in babies to reach adult activity levels.³² Plasma PON1 activity reaches adult levels in mice at 3 weeks of age.³³ When the human *PON1*_{Q192} and *PON1*_{R192} transgenes, including their respective 5' regulatory regions, are expressed in *PON1*^{-/-} mice, the time course is the same as observed in wild type mice with activity peaking at ≈ 3 weeks of age, indicating a strong conservation of PON1 regulatory elements between humans and mice.³² A study carried out in collaboration with the University of California Children's Health Study Program showed a large variability of PON1 activity levels among both mothers and newborns (Fig. 3).³⁴ The average PON1 activity levels in the newborns were comparable with the PON1 levels in the *PON1* transgenic mice allowing for the prediction of the relative sensitivity to CPO and DZO. The predicted range of sensitivity for CPO exposure between the newborn with the lowest PON1 activity level and the mother with the highest PON1 activity level was 131- to 164-fold and for DZO ≈ 65 -fold. A major concern would be for the mothers with low PON1 activity levels to protect their fetuses from exposure to these OP compounds. The data supporting these concerns are discussed here.




ROLE OF PON1 IN PRE- AND POSTNATAL OP EXPOSURES IN ANIMAL STUDIES

OP insecticides are developmental neurotoxicants that can lead to permanent brain damage. Concern for prenatal and postnatal exposure to OP insecticides such as CPS and their potential effect in neurodevelopment and neurotoxicity has prompted many studies on OP exposures in dams, fetuses, and pups. Several *in vitro* studies have shown potential neurodevelopmental effects of CPO at levels that do not inhibit acetylcholinesterase (AChE).³⁵ This is of special interest as chronic low-level environmental OP exposures are common.

PON1, one of the main CPO detoxifying enzymes, is modulated by age. As mentioned previously, studies of PON1 expression during development in transgenic mice expressing either human *PON1*_{Q192R} alloforms (*tgHuPON1*_{Q192} and *tgHuPON1*_{R192}) indicated that PON1 activity is low at birth and plateaus at 3 to 4 weeks of age.³² This finding was in agreement with previous studies in wild-type mice and rats,^{33,36} suggesting that the developing brain may be more susceptible to the toxic effects of certain OPs. Creation of the *PON1*^{-/-} mouse was key to demonstrate the role of PON1 in detoxification of certain OPs such as CPO and DZO, and their parent compounds.^{9,17} The “humanized” *tgHuPON1* mice generated on the *PON1*^{-/-} background provided a better


understanding of the effect of PON1 Q192R polymorphism in OP exposures *in vivo*. As observed in studies injecting the two PON1 alloforms in *PON1*^{-/-} mice,⁹ adult transgenic mice carrying only the *PON1*_{Q192} allele were more sensitive to CPS and CPO exposure than *tgHuPON1*_{R192} mice.³⁷

There are very few studies on pre- and postnatal effects of OP exposures in relation to PON1. In a study of oral gestational exposure to CPS in rats from gestational days (GD) 14 to 18, the authors concluded that fetal brain total cholinesterase (AChE and butyrylcholinesterase [BChE]) was able to recover faster between dosages than maternal brain total cholinesterase.³⁸ As expected, PON1 activity in fetal tissues (liver and placenta) was quite low compared with the maternal tissues, providing little potential for CPS detoxification in rat fetuses by PON1. A similar study using C57BL/6 dams chronically exposed to CPS via subcutaneous injection from GD 6 to GD 17 also showed fetal resistance to CPS toxicity, with fetal brain AChE less inhibited than maternal brain AChE.³⁹ To study the neurotoxic effects in fetuses and the protective effect of maternal PON1 Q192R polymorphism in repeated CPO exposures, a more recent gestational study has been published using wild type, *PON1*^{-/-}, *tgHuPON1*_{Q192}, and *tgHuPON1*_{R192} mice.⁴⁰ Pregnant female mice were dermally exposed from GD 6 to GD 17 to doses of CPO that caused minor inhibition of maternal brain AChE in wild type mice. Maternal



biomarkers of OP exposure (plasma BChE, carboxylesterase, red blood cell acylpeptide hydrolase, and brain AChE) showed significantly decreased activity, independently of the mouse strain tested (except for brain AChE activity in wild-type dams). However, only fetal plasma BChE activity seemed to be affected

by CPO toxicity, despite reported fast recovery of cholinesterases in fetuses.³⁸ These effects seemed to be modulated by maternal *PON1* activity levels and dependent on the maternal *PON1* Q192R polymorphism, as fetuses had extremely low plasma *PON1* activity. A much more rapid CPO detoxification in



maternal plasma could prevent CPO from reaching fetal brain and inhibiting AChE. Conversely, studies reporting some fetal brain AChE inhibition used CPS,^{38,39} which is first metabolized by cytochrome P450s to the reactive CPO in maternal and fetal tissues (CPS can cross the placenta) and then detoxified. As predicted from other studies,^{9,37} fetuses of *PON1*^{-/-} dams were the most susceptible to chronic CPO exposure, followed by fetuses from *tgHuPON1*_{Q192} dams. These findings were supported by gene expression data obtained in this same study. Following CPO exposure, brain from fetuses of *tgHuPON1*_{Q192} dams, compared with fetal brain from *tgHuPON1*_{R192} dams, were enriched in gene sets related to the mitochondrial respiratory chain, lipid metabolism, cell cycle, vesicle membranes, and neurotransmission by glutamate receptors, among many others.⁴⁰ Therefore, this study demonstrated that maternal PON1 status could modulate the effects of gestational exposure to CPO on fetal brain gene expression and biomarkers of exposure. An earlier study conducted in C57BL/6 mice reported similar gene sets affected in fetal brain resulting from CPS exposure to dams.³⁹

Studies on neonatal OP exposures have been very important in demonstrating the role of PON1 status in determining susceptibility to developmental neurotoxicity. Repeated daily exposure of wild type, *PON1*^{-/-}, *tgHuPON1*_{Q192}, and *tgHuPON1*_{R192} mice to CPO from postnatal days (PNDs) 4 to 21 resulted in changes in cerebellar gene expression, body weight, and neurobehavioral deficits.^{41,42} In humans, PND 4 to 21 would parallel the neurodevelopmental period comprised between late gestation and the first 2 years of life. A 2.5-fold difference in resistance to CPO between wild type and *PON1*^{-/-} mice was already observable in 4-day-old mice.⁴¹ Although the doses of CPO used in that study were low and not lethal to *PON1*^{-/-} mice, chronic exposure to CPO reduced brain AChE activity more significantly in the *PON1*^{-/-} and *tgHuPON1*_{Q192} mice, strains that have lower capacity of CPO detoxification. These 2 strains of mice also showed the same cerebellar pathways affected by exposure, mostly related to mitochondrial dysfunction and oxidative phosphorylation,⁴¹ consistent with other studies that have associated oxidative stress with OP exposures.⁴³ Extensive neurobehavioral testing of the CPO-exposed *PON1*^{-/-} mice only showed changes in startle latency and dose-related transient hyperkinesia.⁴² Perhaps the effects of CPO exposure in mice are age-dependent, or alternative

neurobehavioral tests assessing other brain neurotransmitter systems and social interactions should have been tested. Thus, PON1 protection against CPO toxicity during postnatal development is determined by the level of PON1 expression, with juvenile mice with low PON1 status (*tgHuPON1*_{Q192}) being more susceptible to CPO toxicity than *tgHuPON1*_{R192}.

PON1 AS A BIOMARKER OF SUSCEPTIBILITY TO NEURODEVELOPMENTAL EFFECTS

Children are particularly susceptible to environmental toxicants. OP insecticides such as CPS, the most used OP insecticide in the United States, can reach fetal tissues by crossing the placenta, with exposure continuing after birth through breast milk.⁴ Of note is that the blood-brain barrier is not completely developed until around the first year of life and, therefore, does not protect against chemicals crossing into the brain. There have been numerous studies on the effects of CPS in pregnant women and children, most of them accurately reviewed in a previous study.³⁵ As the present review focuses on PON1, we limit the studies discussed to those that included assessment of both PON1 genotype and phenotype, as genotype alone is uninformative.^{31,34}

Given the role of PON1 in protecting against OP exposures and the lower PON1 levels at birth, the study of the role of PON1 in OP exposures and related outcomes during pregnancy and childhood continues to be the focus of intense research. The lower PON1 levels in children were first reported in 1963.⁴⁴ However, because we now know that the human serum arylesterase activity is catalyzed by PON1,^{18,24} the relationship of PON1 levels with neurochemical and neurobehavioral changes following OP exposures was not evident until recently.

Several reports on a multiethnic birth cohort study at the Mount Sinai Medical Center in New York City have documented effects on fetal growth and neurodevelopment from *in utero* exposures to CPS in relationship with maternal PON1 activity and genotype. In their first study, smaller head circumferences were reported in babies from mothers with low PON1 activity than in the offspring from mothers with higher PON1 arylesterase activity or nonexposed mothers.⁴⁵ A later study by the same investigators on prenatal exposures to OPs and other pesticides in another cohort in the same

geographical area confirmed their previous finding of lower PON1 arylesterase activity leading to decreased head circumferences in babies.⁴⁶ Additionally, they found statistically significant relationships between certain urinary dialkylphosphate metabolites (DAPs), low PON1 status (low PON1 arylesterase activity and *PON1*_{QQ192} genotype), and decreased birth weight and birth length. They also assessed abnormalities in neonatal behavior and primitive reflexes with the Brazelton Neonatal Behavioral Assessment Scale, an index used to assess newborn's abilities. There was an increased number of abnormal primitive reflexes in neonates from mothers with low PON1 arylesterase activity and high DAP metabolite levels during pregnancy.⁴⁷ In a follow-up study of the cohort at ages 1 to 2 and 6 to 9 years, the authors evaluated the effects of early-life exposures in development.⁴⁸ In this case, the Bayley Scales of Infant Development was used. The scale provides age-standardized norms of mental and psychomotor development. The results of years 1 to 2 were somewhat contradictory in terms of maternal *PON1*₁₉₂ genotype, probably due to sample size and heterogeneous race/ethnicity. However, the findings suggested that prenatal exposure to OPs (estimated by maternal urinary DAPs) had a detrimental effect on perceptual reasoning (cognitive development) in 1- to 2-year-old infants. This evidence was stronger in 6- to 9-year-old children of mothers homozygous for the *PON1*_{Q192} polymorphism. No effect of PON1 arylesterase activity from maternal blood or cord blood on the neurodevelopmental assessment performed was noted. To our knowledge, this was the first study to examine a possible association between *PON1* Q192R genotype and neurobehavioral endpoints in children.


The CHAMACOS (Center for the Health Assessment of Mothers and Children of Salinas) study is a longitudinal birth cohort study from an agricultural Mexican-American community from the Salinas Valley in California. Farmworker mothers had been exposed to relatively high levels of OP pesticides during pregnancy, as assessed by urinary DAP metabolites. When measuring PON1 status in mothers and their babies, at birth, children's PON1 levels were one-fourth the level of the mothers, with a predicted sensitivity to DZO exposure of 26-fold versus 14-fold among the mothers.³⁴ The calculated range of sensitivity to CPO exposure was of 131- to 164-fold between the *PON1*_{QQ192} newborn with lowest PON1 status and the *PON1*_{RR192} mother with highest PON1 status. To

our knowledge, that was the first study to assess PON1 status in a cohort of mothers and babies exposed to OPs. Prenatal maternal urinary DAPs were associated with detrimental pervasive and mental development in children at age of 2, as measured with the Bayley Scales of Infant Development.⁴⁹ Decreased mental development scores appeared to be related to the child's promoter *PON1*_{-108T} allele, whereas psychomotor developmental scores in *PON1*_{QQ192} children were inversely associated with urinary DAP levels.⁵⁰ At ages 5 to 7, full-scale IQ scores tended to be lower in *PON1*_{-108TT} children and in children from mothers with higher DAP levels and lower PON1 arylesterase activity during pregnancy, with the latter also showing lower verbal comprehension.⁵¹ Altogether, these results suggest that PON1 genotype and low activity may be related to adverse cognitive functioning in vulnerable children (ie, children from mothers with low PON1 activity exposed to OPs during pregnancy).

BIOMONITORING OF OP EXPOSURES

Primary routes of OP exposure in the United States are through food consumption and spray drift in agricultural communities.^{10,52} Although the states of Washington and California have ongoing biomonitoring programs of their agricultural workers, who can potentially suffer acute occupational exposures to the insecticides sprayed, there are a lack of methods sensitive enough to quantify nonoccupational low-level chronic OP exposures in the general population. Biomonitoring of acute and chronic environmental exposures is especially important for pregnant women and children, who are more vulnerable to the effect of neurotoxins. Therefore, improved assessment of children's exposures is highly needed.⁵³

Upon entering the human body, the parent OP organophosphorothioates are either detoxified by specific cytochrome P450s (and eliminated in the urine) or converted to their highly toxic oxon forms (Fig. 4). The highly toxic oxons interact with serine active-site enzymes (eg, AChE and BChE) creating a covalent bond with their active site serine, which ages to an irreversible inhibitor of the enzyme. The adducted protein is stable and will remain in circulation until degradation, which depends on the protein's half-life in circulation (11 days for plasma BChE and 33 days for red blood cell AChE). The oxons can undergo spontaneous or enzymatic (ie, PON1) hydrolysis resulting in the formation of DAP metabolites and an OP-specific



leaving group. These metabolites do not show inhibitory properties and are eliminated in the urine.

Urinary DAP metabolites and cholinesterase enzymatic inhibition assays are the most common methods used for biomonitoring OP exposures.⁵⁴ The 2 approaches offer advantages and disadvantages. Measurement of 6 DAP metabolites has been used to assess exposure of at least 28 OPs and is not an invasive method because it uses urine samples.⁵⁵ However, OP metabolites have short half-lives, ranging between 24 and 48 hours, the OP or mixture of OPs involved in the exposure may form the same metabolites during hydrolysis and, therefore, the OP of exposure cannot be distinguished, and the metabolites cannot be discriminated from direct environmental exposure to

non-toxic OP degradation products, which would result in overestimation of the exposure.⁵⁴ As OPs target cholinesterases, among other serine hydrolases, inhibition of their activity in blood has been used for many years as a surrogate to estimate the level of brain AChE inhibition. Inhibition of plasma BChE is one of the early biomarkers of OP exposure commonly used. The Ellman colorimetric enzymatic assays,⁵⁶ which use red blood cells to determine AChE activity (with acetylthiocholine as substrate) or plasma for BChE activity (with butyrylthiocholine as substrate), are quite accurate, reliable, and inexpensive. Although used for monitoring agricultural workers, the drawbacks of these assays are significant. The requirement of a pre-exposure sample to be used as the individual's

baseline activity, the high intra- and interindividual variability, and the inability to assess chronic low-level exposures that usually cause no cholinesterase inhibition are some of the disadvantages of the Ellman assays.⁵⁴

A more accurate method for biomonitoring OP exposures is needed. An ideal biomonitoring protocol should accurately quantify exposures and provide some information about the OP compound, should be sensitive enough to monitor low-level exposures, should be automatable and reproducible, and should require samples obtained through the least invasive route possible. In recent years, a focus on mass spectrometry (MS) as a tool for biomonitoring OP exposures has emerged.⁵⁷ MS provides high-sensitivity methods for targeting post-translational modifications in proteins, including OP adducts. A myriad of biological processes result in adducted proteins and DNA, so in the recent years, the general study of adducts on biological molecules has been termed *adductomics*. Mass spectrometric analyses provide significant improvements since they can target any biomarker of OP exposure, not just the cholinesterases. Furthermore, proteins are very abundant, their half-lives are much longer than those of urinary metabolites, and baseline activity measurements are not necessary.⁵⁷ Although blood collection is invasive and requires the sample to be processed and stored properly, the high sensitivity provided by MS has been demonstrated in preliminary experiments to provide adequate sensitivity for quantifying OP exposures from dried blood spots (J. Marsillach et al., unpublished data, 2016). Dried blood spot samples are much easier to collect from finger sticks as well as easier to ship and store. They should also allow for analysis of OP exposures from archived dried blood spots from newborn heel sticks.

CONCLUSIONS AND FUTURE DIRECTIONS

Early-life exposures have important effects on brain development that can lead to permanent damage, affecting children's future development in society and increasing their susceptibility to develop neurodegenerative diseases. Genetic variability of the *PON1* gene and the resulting effects on protein structure and levels have provided an early, well-characterized example of gene-environment interaction. All of the early research examined the role that PON1 played in modulating exposures to OP insecticides. Cloning and characterizing the PON1 cDNA along with purifying the 2 Q192R alloforms

of PON1 allowed for the determination of the effects of this coding region polymorphism on the catalytic efficiency of OP hydrolysis. The development of the PON1 genetically variable mice has provided an invaluable asset for understanding the physiological function of PON1.^{17,37} For many years, it was thought that high metabolizers of PO would be resistant to exposures to parathion/PO, however, experiments from our laboratory showed this not to be the case and demonstrated the importance of high catalytic efficiency for determining whether PON1 could protect against specific exposures.⁹ These experiments showed that the genetic variability in PON1 governed primarily sensitivity to the oxons of CPS and DZS with some protection afforded to exposures to the respective parent organophosphorothioates. These experiments clearly pointed out that hydrolysis of OPs with *in vitro* assays was not a good indicator of the ability of PON1 to protect against exposure. PO and the nerve agents soman and sarin provide good examples of this point. The development of a protocol for generating native recombinant human PON1 (rHuPON1) from an *Escherichia coli* expression system allowed for the characterization of the protective capacity of PON1 under physiological conditions and at the same time demonstrated the potential to make use of rHuPON1 as a therapeutic for treating OP exposures.¹⁸

Another physiological function of PON1 in preventing cardiovascular disease came to light with the discovery that PON1 on the high-density lipoprotein particles was responsible for preventing the oxidation of low-density lipoprotein particles.⁵⁸ This observation initiated many studies on the relationship of PON1 genetic variability to various oxidative stress-related diseases. This topic is not covered in this review, but is worth mentioning for readers who would like to follow up other gene-environment interactions involving genetic variability of PON1. These studies also emphasize the importance in epidemiologic studies of examining PON1 status, which reveals the activity of PON1 as well as the Q192R phenotype of individuals. Studies that include PON1 status have found that low PON1 activity levels are a risk factor not only for OP exposure but also for cardiovascular disease.⁵⁹⁻⁶¹ Studies that examine only SNPs are missing the most important measure of risk, the activity levels of PON1, and have often led to inconclusive results.³¹ The assays for determining PON1 status are high throughput and, therefore, convenient for use in most laboratories.

Another important point to note in summarizing PON1 gene-environment interactions in early life

exposures is the developmental variability of PON1 where newborns have much lower PON1 levels (also variable among infants) than adults and are thereby more sensitive to exposures for which PON1 modulates risk.

Epidemiologic studies with appropriate measurement of PON1 status as a biomarker of susceptibility coupled with accurate measures of exposures are still needed. The focus on MS analysis of OP-adducted biomarker proteins has several advantages over the Ellman assays or the urinary DAP metabolite analyses. No additional blood draw is required to determine subjects' baseline activity levels, which would eliminate thousands of blood draws from agricultural workers before the spray season starts, and avoid the difficulty of obtaining multiple blood draws. The

MS analyses simply provide an accurate determination of the percentage adduction of the active-site serine in biomarker proteins. Additionally, adducted proteins have a much longer half-life than DAP metabolites, increasing the window of time for exposure detection. Additionally, the high sensitivity of MS also provides some information about the OP to which the individual was exposed. The use of finger-stick/dried blood spot analyses significantly simplifies sample collection, shipping and archiving. MS is still an emerging field, and implementation of this technology in clinical laboratories is still underway. However, thanks to the significant accomplishments obtained in recent years, the future of MS as a tool to quantify children's exposures at any life stage is very promising.

REFERENCES

- World Health Organization. Public health impact of pesticides used in agriculture. Geneva, Switzerland: WHO; 1990.
- US Environmental Protection Agency. Pesticides industry sales and usage report. Washington, DC: US EPA; 2011.
- Mowry JB, Spyker DA, Cantilena LR Jr, et al. 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st annual report. *Clin Toxicol (Phila)* 2014;52:1032–283.
- Grandjean P, Landrigan PJ. Neurobehavioral effects of developmental toxicity. *Lancet Neurol* 2014;13:330–8.
- Aldridge WN. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. *Biochem J* 1953;53:110–7.
- Aldridge WN. Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. *Biochem J* 1953;53:117–24.
- Brealey CJ, Walker CH, Baldwin BC. A-esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. *Pestic Sci* 1980;11:546–54.
- Furlong CE, Cole TB, Jarvik GP, et al. Pharmacogenomic considerations of the paraoxonase polymorphisms. *Pharmacogenomics* 2002;3:341–8.
- Li WF, Costa LG, Richter RJ, et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. *Pharmacogenetics* 2000;10:767–79.
- Armstrong JL, Yost MG, Fenske RA. Development of a passive air sampler to measure airborne organophosphorus pesticides and oxygen analogs in an agricultural community. *Chemosphere* 2014;111:135–43.
- Martnez Vidal JL, Egea Gonzalez FJ, Martnez Galera M, Castro Cano ML. Diminution of chlorpyrifos and chlorpyrifos oxon in tomatoes and green beans grown in greenhouses. *J Agric Food Chem* 1998;46:1440–4.
- Yuknavage KL, Fenske RA, Kalman DA, et al. Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. *J Toxicol Environ Health* 1997;51:35–55.
- Nolan RJ, Rick DL, Freshour NL, et al. Chlorpyrifos: pharmacokinetics in human volunteers. *Toxicol Appl Pharmacol* 1984;73:8–15.
- Main AR. The role of A-esterase in the acute toxicity of paraoxon, TEEP and parathion. *Can J Biochem Physiol* 1956;34:197–216.
- Costa LG, McDonald BE, Murphy SD, et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. *Toxicol Appl Pharmacol* 1990;103:66–76.
- Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. *Toxicol Lett* 1995;76:219–26.
- Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. *Nature* 1998;394:284–7.
- Stevens RC, Suzuki SM, Cole TB, et al. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from *Escherichia coli* protects against organophosphate poisoning. *Proc Natl Acad Sci U S A* 2008;105:12780–4.
- Ortigoza-Ferado J, Richter RJ, Hornung SK, et al. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. *Am J Hum Genet* 1984;36:295–305.
- Geldmacher M, Diepgen TL. The human serum paraoxonase - Polymorphism and specificity. *Toxicol Environ Chem* 1988;18:79–196.
- Eckerson HW, WYTE CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. *Am J Hum Genet* 1983;35:1126–38.
- Hassett C, Richter RJ, Humbert R, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. *Biochemistry* 1991;30:10141–9.
- Humbert R, Adler DA, Distechi CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. *Nat Genet* 1993;3:73–6.
- Adkins S, Gan KN, Mody M, et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at

- position 191, for the respective A or B allozymes. *Am J Hum Genet* 1993;52:598–608.
25. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. *J Toxicol Environ Health* 1993;40:337–46.
 26. Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. *Nat Genet* 1996;14:334–6.
 27. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. *Pharmacogenetics* 1999;9:745–53.
 28. Huen K, Richter R, Furlong C, et al. Validation of PON1 enzyme activity assays for longitudinal studies. *Clin Chim Acta* 2009;402:67–74.
 29. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. *Circ Cardiovasc Genet* 2008;1:147–52.
 30. Jarvik GP, Jampsa R, Richter RJ, et al. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. *Pharmacogenetics* 2003;13:291–5.
 31. Furlong CE, Richter RJ, Li WF, et al. The functional consequences of polymorphisms in the human PON1 gene. In: Mackness B, Mackness M, Aviram M, Paragh G, eds. *The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism*. New York, NY: Springer; 2008:267–81.
 32. Cole TB, Jampsa RL, Walter BJ, et al. Expression of human paraoxonase (PON1) during development. *Pharmacogenetics* 2003;13:357–64.
 33. Li WF, Matthews C, Distechi CM, et al. Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. *Pharmacogenetics* 1997;7:137–44.
 34. Furlong CE, Holland N, Richter RJ, et al. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. *Pharmacogenet Genomics* 2006;16:183–90.
 35. Eaton DL, Daroff RB, Autrup H, et al. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. *Crit Rev Toxicol* 2008;38(suppl 2):1–125.
 36. Costa LG, Giordano G, Cole TB, et al. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. *Toxicology* 2013;307:115–22.
 37. Cole TB, Walter BJ, Shih DM, et al. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. *Pharmacogenet Genomics* 2005;15:589–98.
 38. Lassiter TL, Padilla S, Mortensen SR, et al. Gestational exposure to chlorpyrifos: apparent protection of the fetus? *Toxicol Appl Pharmacol* 1998;152:56–65.
 39. Moreira EG, Yu X, Robinson JF, et al. Toxicogenomic profiling in maternal and fetal rodent brains following gestational exposure to chlorpyrifos. *Toxicol Appl Pharmacol* 2010;245:310–25.
 40. Cole TB, Li WF, Co AL, et al. Repeated gestational exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1) modulated effects in maternal and fetal tissues. *Toxicol Sci* 2014;141:409–22.
 41. Cole TB, Beyer RP, Bammler TK, et al. Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression. *Toxicol Sci* 2011;123:155–69.
 42. Cole TB, Fisher JC, Burbacher TM, et al. Neurobehavioral assessment of mice following repeated postnatal exposure to chlorpyrifos-oxon. *Neurotoxicol Teratol* 2012;34:311–22.
 43. Milatovic D, Gupta RC, Aschner M. Anticholinesterase toxicity and oxidative stress. *Scientific World Journal* 2006;6:295–310.
 44. Augustinsson KB, Barr M. Age variation in plasma arylesterase activity in children. *Clin Chim Acta* 1963;8:568–73.
 45. Berkowitz GS, Wetmur JG, Birman-Deych E, et al. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. *Environ Health Perspect* 2004;112:388–91.
 46. Wolff MS, Engel S, Berkowitz G, et al. Prenatal pesticide and PCB exposures and birth outcomes. *Pediatr Res* 2007;61:243–50.
 47. Engel SM, Berkowitz GS, Barr DB, et al. Prenatal organophosphate metabolite and organochlorine levels and performance on the Brazelton Neonatal Behavioral Assessment Scale in a multiethnic pregnancy cohort. *Am J Epidemiol* 2007;165:1397–404.
 48. Engel SM, Wetmur J, Chen J, et al. Prenatal exposure to organophosphates, paraoxonase 1, and cognitive development in childhood. *Environ Health Perspect* 2011;119:1182–8.
 49. Eskenazi B, Marks AR, Bradman A, et al. Organophosphate pesticide exposure and neurodevelopment in young Mexican-American children. *Environ Health Perspect* 2007;115:792–8.
 50. Eskenazi B, Huen K, Marks A, et al. PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero. *Environ Health Perspect* 2010;118:1775–81.
 51. Eskenazi B, Kogut K, Huen K, et al. Organophosphate pesticide exposure, PON1, and neurodevelopment in school-age children from the CHAMACOS study. *Environ Res* 2014;134:149–57.
 52. US Environmental Protection Agency. *Organophosphorus cumulative risk assessment – 2006 update*. Washington, DC: US EPA; 2006.
 53. Landrigan PJ, Kimmel CA, Correa A, et al. Children's health and the environment: public health issues and challenges for risk assessment. *Environ Health Perspect* 2004;112:257–65.
 54. Marsillach J, Costa LG, Furlong CE. Protein adducts as biomarkers of exposure to organophosphorus compounds. *Toxicology* 2013;307:46–54.
 55. Barr DB, Bravo R, Weerasekera G, et al. Concentrations of dialkyl phosphate metabolites of organophosphorus pesticides in the U.S. population. *Environ Health Perspect* 2004;112:186–200.
 56. Ellman GL, Courtney KD, Andres V Jr, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88–95.
 57. Marsillach J, Hsieh EJ, Richter RJ, et al. Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures. *Chem Biol Interact* 2013;203:85–90.
 58. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett* 1991;286:152–4.
 59. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. *Arterioscler Thromb Vasc Biol* 2000;20:2441–7.
 60. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. *J Clin Invest* 2011;121:2693–708.
 61. Furlong CE, Suzuki SM, Stevens RC, et al. Human PON1, a biomarker of risk of disease and exposure. *Chem Biol Interact* 2010;187:355–61.